key: cord-0773552-b96gjbww
authors: Petrone, Linda; Petruccioli, Elisa; Vanini, Valentina; Cuzzi, Gilda; Fard, Saeid Najafi; Alonzi, Tonino; Castilletti, Concetta; Palmieri, Fabrizio; Gualano, Gina; Vittozzi, Pietro; Nicastri, Emanuele; Lepore, Luciana; Antinori, Andrea; Vergori, Alessandra; Caccamo, Nadia; Cantini, Fabrizio; Girardi, Enrico; Ippolito, Giuseppe; Grifoni, Alba; Goletti, Delia
title: A whole blood test to measure SARS-CoV-2 specific response in COVID-19 patients
date: 2020-10-10
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2020.09.051
sha: 51d112c62156f3fb5d675691f9804763a4a8dccf
doc_id: 773552
cord_uid: b96gjbww

OBJECTIVES: To examine whether specific T-cell-responses to SARS-CoV-2 peptides can be detected in COVID-19 using a whole-blood experimental setting, which may be further explored as potential diagnostic tool. METHODS: We evaluated IFN-γ levels after stimulating whole-blood with spike and remainder-antigens peptides megapools (MP) derived from SARS-CoV-2 sequences; IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17A, eotaxin, basic FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF, RANTES, TNF-α, VEGF were also evaluated. RESULTS: IFN-γ-response to spike and remainder-antigens MPs was significantly increased in 35 COVID-19-patients compared to 29 “NO COVID-19”-individuals (medians spike-MP: 0.26 vs 0, p=0.0002; medians remainder-antigens-MP: 0.07 vs 0.02; p=0.02). This response was detected independently of patients’ clinical parameters. IFN-γ-response to SARS-CoV-2-unrelated antigens CMV and SEB was similar in COVID-19 compared to NO-COVID-19-invididuals (median CMV: 3.46 versus 5.28, p=0.16; median SEB: 12.68 versus 15.05; p=0.1). In response to spike-MPs in COVID-19- compared to “NO COVID-19”-individuals, we found significant higher median of IL-2 (50.08 vs 0, p=0.0018), IFN-γ (90.16 vs 0, p=0.01), IL-4 (0.52 vs 0, p=0.03), IL-13 (0.84 vs 0, p=0.007) and MCP-1 (4602 vs 359.2, p=0.05). CONCLUSIONS: Immune response to SARS-CoV-2 peptides in a whole-blood assay is associated to COVID-19 and it is characterized by both Th1 and Th2 profile. This experimental approach may be useful for developing new T-cell based diagnostic tests for disease and vaccine settings.

COVID-19 is an emerging respiratory infection caused by SARS-CoV-2 with an estimated global 67 burden of more than 30 million (1). Diagnosis is based on RT-PCR targeting one or more viral 68 genes using nasopharyngeal swabs or other respiratory specimens (2). High SARS-CoV-2-69 specific IgG-levels correlate with viral-neutralizing antibodies (3). However, IgM/IgG-based tests 70 may show cross-reactions with other coronaviruses (2). 71

Ethical Committee of Lazzaro Spallanzani National Institute of Infectious Diseases (INMI) approved 98 the study (58/2020) that was conducted in April 8 th -July 1 st . Informed, written consent was required 99 to consecutively enroll patients and controls by physicians. The 35 COVID-19-patients (all with 100 positive nasopharyngeal swab for SARS-CoV2) were classified as mild, moderate, severe and 101 critical, according to WHO (4). For controls, 29 "NO COVID-19"-individuals were enrolled and were 102 healthy donors (HDs) (n=11) volunteers from our laboratory or a convenience sample of 103 consecutively patients hospitalized for other diseases as bacterial pneumonia (n=3), latent 104 tuberculosis infection (n=10), active tuberculosis under therapy (n=4), echinococcosis (n=1). 105

Demographic and clinical information were collected at enrollment. 106

Stimuli 108 SARS-CoV-2 peptide pools (MegaPools, MPs) have been designed and validated (12,13,24). The 109 megapool design was carried out on the Wuhan-Hu-1 reference isolated (GenBank ID:MN908947). 110

To ensure a comprehensive assessment of spike-specific reactivity, the main target of vaccine 111 candidates, overlapping 15-mers by 10 spanning the entire protein were synthetized and pooled 112 separately (spike; n=253). The remainder of the SARS-CoV-2 proteome was filtered applying the 113 7-allele-method CD4-T-cell prediction (22) with a cutoff of ≤20, aiming to predict promiscuous 114 epitopes with the capability to bind across the most common HLA-class II specificities (remainder-115 antigens; n=221). 116

Six hundred microliter of whole-blood were stimulated or not with spike-or remainder-antigens-MP, 124 CMV-MP as unrelated antigen and SEB as positive control. Plasma was harvested after 6/24 hours 125 of stimulation at 37°C (5% CO2) and stored at -80°C . IFN-γ levels were evaluated by ELISA, 126 according to manufacturer's instructions (www.quantiFERON.com). IFN-γ values were subtracted 127 from the unstimulated-or dimethyl-sulfoxide control-control. Detection limit of the test is 0.065 128 IU/mL. 129

SARS-CoV-2 IgG levels were measured by ELISA according to manufacturer's instructions 132 (DIESSE Diagnostica Senese S.p.a., Monteriggioni, Italy). The ratio between the optical density of 133 the sample and that of the cut-off reagent (index) has been calculated. The samples were scored 134 positive (index >1.1), doubtful (index between 1.1 and 0.9), negative (index is <0.9). In "NO 135 COVID-19"-group, ELISA-positive samples were tested with an indirect immunofluorescence 136 assay, using home-made slides prepared with SARS-CoV-2-infected Vero E6-cells. 137 138

Cytokines, chemokines and growth factors (IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-140   10, IL-12p70, IL-13, IL-15, IL-17A, eotaxin, basic FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1,  141 MIP-1α, MIP-1β, PDGF, RANTES, TNF-α, VEGF) were evaluated in harvested plasma using Bio-142

Plex Pro Human Cytokine 27-plex Assay panel and the MagPix system (all from Bio-Rad, 143

Hercules, CA, USA), according to manufacturer's instructions. Raw data were generated using the 144 Bio-Plex Manager software. Concentrations below the detection range were considered as zero. 145

Concentrations above the detection range were converted to the highest value of the standard 146 curve. Analyte levels were subtracted from the unstimulated control. Samples with acquired beads 147 count <50 were excluded from the final analysis. 148

Data were analyzed using SPSS software (Version 19 for Windows, Italy SRL, Bologna, Italy), and 153

Graph Pad (GraphPad Prism 8 XML ProjecT). Medians and interquartile ranges (IQR) were 154 calculated; the following tests were used: Kruskal-Wallis test for comparisons among groups, 155

Mann-Whitney U test with Bonferroni correction for pairwise comparisons, Chi-square test for 156 categorical variables; receiver-operator characteristic (ROC) analysis for evaluating diagnostic 157 performance; Spearman Rank Correlation for correlations and r s >0.7 was considered high 158 correlation, 0.7<r s >0.5 moderate correlation and r s <0.5 low correlation. 159

COVID-19-group showed a significantly higher median age (p=0.006) and a higher number of 162 female compared to the "NO COVID-19"-group (p=0.23) ( Table 1) the COVID-19-and "NO COVID-19"-groups were found using SEB-(median: 12.68, IQR 11.22-189 15.03 versus median 15.05, IQR 12.58-17.50; p=0.1) and CMV-stimulus (median: 3.46, IQR 0.14-190 8.47 versus median: 5.28, IQR 1.71-12.9; p=0.16), employed as non-specific and -specific 191 stimulation respectively ( Figure 1C -D). Within the "NO COVID-19", no significant differences were 192 found comparing the IFN-γ response to all stimuli between HDs and the controls (p≥0.32). Therapy was evaluated as potential factor impacting the IFN-γ response to SARS-CoV-2 peptides: 232 however, the studied population was too small to perform statistical analysis. 233

The whole-blood response to SARS-CoV-2 response is characterized by Th1 but also Th2 235 cytokines 236

The production of several cytokines, chemokines and growth factors was evaluated in 13 COVID- In this study, we showed the ability to detect T-cell response to SARS-CoV-2-specific peptides 255 using a whole-blood-cytokine release assay. In particular, COVID-19-patients showed a significant 256 high IFN-γ response, although both Th1 and Th2 cytokines were detected. Unrelated SARS-CoV- (11-13,26). Therefore, a more specie-specific peptide selection is needed to fully understand the 276 immune response to SARS-CoV-2. 277

Limits of this work are related to the low number of the patients evaluated within an observational-284 designed study hampering us to fully evaluate the potentials of this immune-based approach for 285 supporting COVID-19 diagnosis. A prospective study design including exposed-individuals followed 286 over time and/or the enrollment of a large cohort of COVID-19-patients at different stages, will 287 undoubtedly help addressing these issues. Also, we did not evaluate by cytometry or ELISPOT the were increased in patients with a positive serology compared to those with a negative serology. No 518 differences were found in response to CMV (C) or SEB (D). IFN-γ was measured by ELISA in 519 stimulated plasma. The horizontal lines represent the median; statistical analysis was performed 520 using the Mann-Whitney test, and p value was considered significant if ≤0.05. Footnotes: IFN:

Footnotes: COVID-19: COronaVIrus Disease 19; N: Number; *: info available from 35 COVID-19 (100%) and 7 (24%) "NO-COVID-19" individuals; § info available from 29 COVID-19 (83%) and 29 "NO COVID-19" (100%) individuals. Origin refer to country of birth. 

A T-416 cell diagnostic test for cystic echinococcosis based on Antigen B peptides

Species specificity preliminary evaluation of an IL-4-based test for the differential diagnosis of 420 human echinococcosis

A Sequence Homology 422 and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV

Development 425 and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes

Automatic Generation of Validated Specific Epitope Sets

Dysregulation of the immune response affects the 430 outcome of critical COVID-19 patients

Updates on T helper type 17 immunity in respiratory disease

Pre-existing immunity to SARS-CoV-2: the knowns and unknowns

Profile of specific antibodies to SARS-CoV-2: The first report

Selected RD1 441 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-442 linked immunosorbent assay and an enzyme-linked immunospot assay